看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。& ^/ w$ K0 q. N X- a3 i) D
g' }* k6 I g, q
1 y+ v- l- A/ y* Y a9 j9 H
Currently available feasibility data for possible combination strategies.
3 `$ ?+ d l1 [. A3 o————————————————————————————————
6 R: y" e; @* g7 Y* F5 C% H6 ^Combination Feasibility according to preliminary data . S: |4 w( c$ d) T$ B+ M0 Y0 ? [
——————————————————————————————————
+ }: `$ |8 ]( V+ I4 k: T) @Bevacizumab + sorafenib Yes, reduced dose
- Y& S9 C! N& _7 X9 e* _Bevacizumab + sunitinib† No / L5 i2 Z5 U4 q7 f: I. G1 g0 I
Bevacizumab + temsirolimus Yes & x8 ?; R6 I! n( B& W- t
Bevacizumab + everolimus Yes % z- I0 _% c1 K B
Sorafenib + sunitinib ? " p7 J1 V7 v# n: V; ^
Sorafenib + temsirolimus Yes, reduced dose
/ w% s( W7 [: R. f6 F# Y; u& gSorafenib + everolimus Yes, reduced dose
* D+ u6 L* Y9 J/ B3 m" zSunitinib + temsirolimus† No
9 Y5 N" m' m `- x MSunitinib + everolimus ? 6 v, L9 d6 r/ W5 Q% ?6 z+ J$ M: N/ ?
Temsirolimus + everolimus ? 8 l( [/ a4 d0 e1 x3 T I h' b
————————————————————$ J# z, u7 s: p5 ~: M# N
†Led to US FDA warning.
: n! ?2 D' j0 C8 s2 Y5 Y7 P4 v?: As yet unattempted combination.
8 w Z3 _; Y+ Z9 r j |